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Abstract  
 
Purpose: Although high glucocorticoid receptor (GR) expression in early-stage estrogen receptor (ER)-
negative breast cancer (BC) is associated with shortened relapse-free survival (RFS), how associated GR 
transcriptional activity contributes to aggressive BC behavior is not well understood. Using potent GR 
antagonists and primary tumor gene expression data, we sought to identify a tumor-relevant gene 
signature based on GR activity that would be more predictive than GR expression alone. 
Design: Global gene expression and GR ChIP-sequencing were performed to identify GR-regulated genes 
inhibited by two chemically distinct GR antagonists, mifepristone and CORT108297. Differentially 
expressed genes from MDA-MB-231 cells were cross-evaluated with significantly expressed genes in 
GR-high versus GR-low ER-negative primary BCs. The resulting subset of GR targeted genes was 
analyzed in two independent ER-negative BC cohorts to derive and then validate the GR activity 
signature (GRsig).  
Results: Gene expression pathway analysis of glucocorticoid-regulated genes (inhibited by GR 
antagonism) revealed cell survival and invasion functions. GR ChIP-seq analysis demonstrated that GR 
antagonists decreased GR chromatin association for a subset of genes. A GRsig comprised of n=74 GR 
activation-associated genes (also reversed by GR antagonists) was derived from an adjuvant 
chemotherapy-treated Discovery cohort and found to predicted probability of relapse in a separate 
Validation cohort (HR=1.9; p= 0.012). 
Conclusions: The GRsig discovered herein identifies high-risk ER-negative/GR-positive BCs most likely 
to relapse despite administration of adjuvant chemotherapy. Because GR antagonism can reverse 
expression of these genes, we propose that addition of a GR antagonist to chemotherapy may improve 
outcome of these high-risk patients.  
  
Research. 
on April 10, 2018. © 2018 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on April 10, 2018; DOI: 10.1158/1078-0432.CCR-17-2793 
Antagonist-derived GRsig for ER− breast cancer… 3 
Translational Relevance 
Glucocorticoid receptor (GR) expression is associated with poor prognosis in estrogen receptor (ER)-
negative breast cancer (BC) patients. GR activation induces gene expression associated with therapy 
resistance and relapse, while GR antagonism improves chemotherapy sensitivity in models of triple-
negative breast cancer (TNBC). After identifying antagonist-modulated GR target genes from cell line 
models, we uncovered a GR signature (GRsig) associated with risk of early recurrence despite adjuvant 
chemotherapy in ER-negative breast cancer. Derived from genes reversed by co-treatment with a GR 
antagonist, we predict the GRsig may be useful to identify high risk patients likely to benefit from adding 
GR antagonism to chemotherapy. 
  
Research. 
on April 10, 2018. © 2018 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on April 10, 2018; DOI: 10.1158/1078-0432.CCR-17-2793 
Antagonist-derived GRsig for ER− breast cancer… 4 
Introduction 
 
Breast cancers (BCs) lacking expression of estrogen receptor (ER), progesterone receptor (PR), 
and HER2 are termed triple-negative breast cancers (TNBCs). The absence of these receptors poses a 
challenge in part because of the lack of druggable targets for TNBC. Resistance (de-novo or acquired) of 
disseminated tumor cells despite adjuvant treatment is also thought to contribute to increased relapse rates 
in early-stage TNBC patients. Recent efforts to distinguish the variable natural history of TNBC have 
used tumor gene expression profiling to divide cancers into four subtypes: basal-like-1, basal-like-2, 
mesenchymal, and luminal androgen receptor (LAR) (1). Additionally, genomic, epigenetic, and 
proteomic analyses of TNBC have revealed several potential therapeutic targets, including androgen 
receptor (AR), EGFR, JAK2, mTOR, PI3K, and BET family proteins (2-7). Despite these advances, 
outside of clinical trials, patients with early-stage TNBC still receive generic adjuvant cytotoxic 
chemotherapy. Therefore, the identification of targetable regulators and molecular signatures of TNBC 
chemoresistance remains a critical need (8).  
Glucocorticoid receptor (GR) is a corticosteroid receptor with both transcription factor and 
chromatin remodeling functions (9). The role of GR in endocrine physiology and metabolism is cell-type 
specific ; its role in cell survival appears to be cancer subtype specific as well. For example, GR 
activation is pro-apoptotic in lymphoid malignancies (10), whereas GR activation is anti-apoptotic and its 
activity is associated with relapse in other cancers (11-20), including ER-negative BC (21-29). 
Interestingly, in ER-positive BC, GR/ER crosstalk appears to contribute to an improved patient outcome 
in high GR-expressing tumors (30-32), highlighting GR’s context-dependent function. Our laboratory and 
others have reported that higher tumor GR transcript (30) and protein (33) expression in early-stage ER-
negative tumors is associated with shorter relapse-free survival (RFS). In a retrospective meta-analysis of 
tumor gene expression from n=354 ER-negative early-stage BC patients, high GR transcript expression 
(NR3C1, top quartile) was associated with poor long-term RFS regardless of whether patients received 
adjuvant chemotherapy (30). Furthermore, GR antagonism has been demonstrated to sensitize cells to 
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chemotherapy-induced cytotoxicity in ovarian (15,18), prostate (16,17,20), and TNBC (24,25). A Phase I 
clinical trial of the GR/PR antagonist mifepristone (300mg/day) administered to BC patients before 
weekly nab-paclitaxel treatment has established the safety and tolerability of this combination (34). 
Together, these data suggest that GR transcriptional activity plays a role in BC aggressiveness and 
chemoresistance, and that GR antagonism is a potential therapeutic strategy. 
In this report, we derived a GR signature using GR-activated gene networks and then identified a 
subset of GR activated genes whose expression changes was also reversed by GR antagonism. GR 
transcriptional activity was antagonized with the steroidal GR/PR antagonist mifepristone (Mif) or the 
highly-selective non-steroidal GR modulator CORT108297 (C297) (35). We performed studies using GR 
antagonists in the context of glucocorticoid (GC)-activated GR to mimic cortisol-activated GR in 
vascularized patient tumors. This experimental design allowed us to identify antagonist-sensitive GC-
mediated GR pathways for both mechanistic insight and to identify a GR activity signature (GRsig) for 
patient stratification.  
  GR is a widely active transcription factor with different tissue-specific activities, and in the 
context of TNBC, GR is likely to regulate many genes that contribute to tumor viability, aggressiveness, 
and eventual recurrence. Therefore, we hypothesized that a network of GR target genes would be a better 
indicator of GR activity in TNBC than GR expression alone. We combined our analyses of antagonist-
modulated GR gene expression in TNBC cells with gene expression data from primary ER-negative BCs 
to identify the GRsig of n=74 genes associated with poor prognosis in early-stage breast cancer despite 
adjuvant chemotherapy. We then validated the GRsig in an independent dataset. Our results suggest that 
1) the GRsig can be used to identify individual early-stage ER-negative patients with a relatively 
increased risk of relapse and 2) adding GR antagonism to adjuvant chemotherapy could reduce tumor GR 
activity, thereby increasing chemotherapy efficacy, and improving clinical outcome in poor-prognosis 
ER-negative BC patients.  
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Materials and Methods 
 
Patients and Samples 
The REMARK (‘REporting recommendations for tumor MARKer prognostic studies’) guidelines 
were used for the retrospective meta-analysis of tissue microarrays (TMA) in this report (36). Details 
regarding primary tumor microarray datasets, standard prognostic variables, adjuvant chemotherapy, and 
a study design flowchart in Supplementary File 1.  
Cell lines and reagents 
The mesenchymal GR-high TNBC cell lines, MDA-MB-231 and SUM-159-PT, were validated and tested 
negative for mycoplasma throughout the course of the experiments. MDA-MB-231 cells were cultured in 
Dulbelcco’s Modified Eagle’s Media (DMEM, Lonza), supplemented with 10% fetal bovine serum (FBS, 
Gemini Bio-Products) and 1% penicillin/streptomycin (Lonza). SUM-159-PT cells were cultured in 
Ham’s F12 Media (Corning), supplemented with 10% FBS and 1% penicillin/streptomycin. Cells were 
cultured at 37°C and 5% CO2. Compounds for cell culture studies were acquired and dissolved as follows: 
Dexamethasone (Sigma) and Mifepristone (Enza) were dissolved into 1 mM stock solutions in ethanol 
(EtOH, Sigma). CORT108297 (C297, Corcept Therapeutics, Menlo Park, CA), and was dissolved at 1 
mM in EtOH. Pharmaceutical-grade paclitaxel (APP Pharmaceuticals) was diluted to 1 mM in EtOH. 
Compounds for the fluorescent polarization assay were dissolved in dimethyl sulfoxide (DMSO) at 50 
mM concentrations, including dexamethasone, mifepristone, CORT108297, CORT118335, 
dihydrotestosterone (DHT), and Compound A (Enzo Life Sciences). Fluorescein-dexamethasone 
(Invitrogen) was dissolved in DMSO in black microcentrifuge tubes at a concentration of 20 mM and 
further diluted as needed in water. For murine xenograft studies, pharmaceutical-grade paclitaxel (APP 
Pharmaceuticals) was suspended in saline and castor oil so that a 50 μL i.p. injection into a 20-gram 
mouse would be a 10 mg/kg dose. CORT108297 was dissolved in EtOH and suspended in sesame oil so 
that a 50 μL i.p. injection into a 20-gram mouse would be a 20 mg/kg dose.  
In vitro GR LBD expression and purification  
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Details regarding the cloning of wild-type GR-LBD (amino acid residues 522-777) into a plasmid, 
obtaining bacmid, and SF9 transfection is described in the Supplementary Materials and Methods. After 
expression of GR LBD, the SF9 cells were pelleted at 3,000 RPM at 4°C, and lysed by sonication in a 
buffer containing 20mM TRIS pH 8.0, 500mM NaCl, 5% glycerol, 0.1% CHAPS, 0.25mM TCEP that 
was supplemented with protease inhibitors and 1.0µM Dex. GR-LBD was purified first using Ni-affinity 
chromatography followed by overnight dialysis with TEV protease to remove the His tag. Extensive 
dialysis into 20mM TRIS pH 8.0, 500mM NaCl, 5% glycerol, 0.1% CHAPS, 0.25mM TCEP was 
performed to obtain non-ligand-bound GR LBD. The final protein was obtained using size exclusion 
chromatography where the protein consistently eluted as a dimer. The purified proteins were concentrated 
to 5mg/ml, flash frozen in 50µl aliquots in N2(l), and stored at -80°C.  
Ligand titration assay via fluorescence polarimetry (FP)  
GR LBD was diluted in assay buffer (20mM TRIS pH 7.5, 50mM NaCl, 0.25mM TCEP) to a 
concentration of 50 nM. After pre-equilibration of GR LBD with both ligand (ranging from 
concentrations ranging from 0 to 4000 nM) and 10nM fluorescein-labeled dexamethasone (F-Dex, Life 
Technologies) for 30 minutes, FP signal was measured using the Beacon 2000 Fluorescence Polarization 
System (Invitrogen). Triplicate FP measurements were scaled to maximal FP and averaged for each 
ligand concentration. Dose response curves for each ligand were generated using GraphPad Prism using 
the log(inhibitor) vs. normalized response curve equation: (Y=100/(1+10^((LogIC50-X)*HillSlope))) 
Western blot analysis of GR protein levels 
MDA-MB-231 cells were grown in 10 cm dishes to 75% confluence in DMEM with 10% FBS. 
Next, the cells were cultured for 48h in phenol red-free DMEM with 2.5% charcoal-stripped FBS media. 
Cells were treated for t=30 minutes with Vehicle (EtOH) or 100nM Dex/Veh, 100 nM Dex/100 nM Mif, 
100nM Dex/100nM C297, or 100nM Dex/100nM C335. Cells were washed with cold PBS, harvested and 
pelleted, and lysed on ice in a buffer containing 20 mM Tris, pH 7.5 containing protease/phosphatase 
inhibitors. Cell lysate was clarified at 15,000 rpm for 10 min and resulting lysate was quantitated using 
the BCA analysis. After denaturing the samples in Laemmli buffer with SDS at 95°C, the samples were 
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resolved on an 8% SDS-page gel, which was then transferred to PVDF membrane. The membrane was 
blocked overnight at 4C with 5% w/v BSA in TBST, then probed for GR (GR-XP D8H2 antibody, Cell 
Signaling) and beta actin (β-Actin 8226, Sigma-Aldrich). After addition of Alexafluor secondary 
antibodies (Invitrogen and LI-COR, respectively), the blot was imaged on the Odyssey infrared imaging 
system (LI-COR). Additional details of immunoblotting protocol can be found the Supplementary 
Materials and Methods.  
Cell viability assay 
MDA-MB-231 and SUM-159-PT cells (n=3 x 104) were seeded in 96-well plates. After culturing in 
DMEM with 10% FBS (for MDA-MB-231) or Ham’s F12 with 5% FBS (for SUM-159-PT), the cells 
were cultured for 48h in charcoal-stripped FBS media (2.5% for MDA-MB-231 or 5% for SUM-159-PT). 
Cells were treated for 72h and 96h with varying concentrations of paclitaxel (0 – 100 nM) in the presence 
of Vehicle/Vehicle, 100 nM Dex/Vehicle, Vehicle/1M C297, or 100 nM Dex/1M C297. The 
sulforhodamine B (SRB) assay was performed as described in the Supplementary Materials and Methods. 
The experiment was performed in three biological replicates per cell line. P-values comparing the means 
of cell death percentages were obtained using the unpaired Student’s t-test (GraphPad).  
Murine TNBC xenograft study 
MDA-MB-231 tumors were established in the right pectoral mammary gland of n=23 five- or six-
week old female SCID mice (Taconic). Tumor volume was measured by caliper and then calculated using 
the elliptical volume equation (24). When tumors reached a volume of 100 – 300 mm3, the mice were 
treated for five days with either 20 mg/kg/day C297 or vehicle one hour prior to 10 mg/kg/day paclitaxel 
or vehicle. Tumor volume was measured by caliper until reaching a volume of approximately 2000 mm3 
or 40 days post-treatment initiation. Tumor data were analyzed using the repeated measures ANOVA 
using SigmaPlot 11.2 (Systat Software), and p-values between treatment groups over time were obtained 
using the Holm–Sidak post-hoc test.  
Gene expression microarray and analysis  
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MDA-MB-231 cells were grown to 80% confluence in 15-cm dishes in DMEM with 10% FBS. 
After culturing cells for 48h in DMEM with 2.5% charcoal-stripped FBS, 2 x 107 cells (per condition) 
were treated with either Vehicle, 100 nM Dex +/- 100 nM C297 or 100 nM Mif for 4, 8, and 12h. 
Following compound exposure, cells were washed in PBS, and lysed in RNA lysis buffer (Qiagen) 
overnight at -80°C. RNA extraction, with accompanying DNase treatment, was performed using the 
RNeasy kit (Qiagen) following the manufacturer’s protocol. A small sample of each condition was 
reverse transcribed to perform Q-RT-PCR as a quality control to test GR-induction of SGK1 by Dex over 
vehicle, and inhibition of that induction by Mif. Duplicate microarray experiments (n=2) for Vehicle, 
Dex, and Dex/Mif conditions were performed along with a single experiment for the Dex/C297 treatment 
condition. The University of Chicago Genomics Core facility carried out the reverse transcription on the 
samples, followed by microarray using the Affymetrix Human U133 Plus 2.0 platform. A detailed 
description of the analysis of gene expression data can be found the Supplementary Materials and 
Methods. After RMA normalization and application of a cut-off of at least +/- 1.3-fold change difference 
in expression for each treatment group versus vehicle, the genes became candidates for further analysis 
when their expression was altered significantly by Dex, and inhibited commonly by Mif and C297 (within 
the same time point as Dex) by at least 25%, in any treatment group. Dex-regulated genes were 
overlapped with a list of n=5,170 differentially-expressed tumor-derived genes (in the same direction) 
from GR-high versus GR-low BCs (30). Ingenuity Pathway Analysis (Qiagen) was performed to 
determine relevant gene expression pathways using the Diseases and Biofunctions setting with a p-value 
cut-off of 0.05 (-log10=1.3). 
GR ChIP-sequencing and analysis 
MDA-MB-231 cells were grown to 80% confluence in 15-cm dishes in DMEM with 10% FBS, 
followed by 48h in DMEM supplemented with 2.5% charcoal-stripped FBS. Cells (n=4 x 107 per 
treatment condition) were treated with Vehicle, or 100 nM Dex +/- 100 nM C297 or 100 nM Mif for 60 
minutes. Cells were cross-linked with 1% formaldehyde, quenched with glycine (final concentration of 
1.25 mM), and harvested. After cell lysis with ChIP lysis buffer (Magna ChIP A Chromatin 
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Immunoprecipitation Kit, EMD Millipore), cells were sonicated to achieve the majority of DNA 
fragments between 200-400 bp. GR was chromatin immunoprecipitated using 3 µg of ChIP-grade XP 
(D8H2) rabbit anti-GR antibody (Cell Signaling); 3 µg of rabbit IgG (Cell Signaling) was used for IgG 
control sample. Chromatin was eluted from GR ChIP and input samples following the manufacturer’s 
protocol. ChIP-sequencing and data analysis is described in depth in the Supplemental Materials and 
Methods. Briefly, sequences were aligned to the human genome (hg19) and peaks were called using 
MACS2. The peaks were then normalized to the Vehicle control using deepTools2 (http://deeptools.ie-
freiburg.mpg.de). ChIPseeker (37) was used to annotate peaks to nearest transcriptional start sites (TSSs) 
of genes. 
Quantitative real-time PCR  
MDA-MB-231 cells were grown to 80% confluence in 6-cm dishes in DMEM (10% FBS, 1% 
penicillin/streptomycin), followed by a 72h serum starvation period in charcoal-stripped DMEM (2.5% 
charcoal-stripped FBS, 1% penicillin/streptomycin). SUM-159PT cells were grown to 80% confluence in 
6-cm dishes in Ham’s F12 (5% FBS, 1 µg/ml hydrocortisone, 5 µg/ml insulin, 1% 
penicillin/streptomycin), followed by a 72h serum starvation period in charcoal-stripped Ham’s F12 (5% 
charcoal-stripped FBS, 1% penicillin/streptomycin). Cells were treated with the following for 4, 8, and 
12-hr: Vehicle (EtOH, 0.2% final volume), Veh/100 nM Dex, Dex/Mif (100 nM each), or Dex/C297 (100 
nM each). Following treatment, cells were washed once with PBS and lysed in 500 µl of RLT buffer 
(Qiagen) supplemented with 1% 2-mercaptoethanol overnight at -80°C. Three biological replicates were 
performed for each compound treatment per cell line. Total RNA extraction, with accompanying DNase 
treatment, was performed using the Qiagen RNeasy kit (Qiagen) following manufacturer’s protocol. After 
reverse transcription, PerfeCTa SYBR Green FastMix (Quanta Biosciences) was used to perform 
quantitative real-time PCR on the resulting cDNA. Primers and controls can be found in the 
Supplementary Materials and Methods. Propagated error (standard deviation) in fold change was 
calculated and p-values were generated with the two-sample Student’s t-test with Welch’s correction for 
unequal variances (GraphPad).  
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siRNA knockdown 
MDA-MB-231 cells were cultured to 80% confluence in 10-cm dishes. siRNA knockdown was 
carried out using the Smartpool (Dharmacon) of four siRNAs against either MCL1 or NNMT. Scrambled 
control pool was used as well (Dharmacon). siRNAs were introduced into cells using the RNAimax 
forward transfection protocol (Invitrogen). Knockdown efficiency was analyzed by Q-RT-PCR (see 
Methods above) normalizing NNMT siRNA pool and MCL1 siRNA pool to the Control siRNA pool. 
After efficient knockdown (48h), cells were treated with Veh/Veh, a range of concentrations (10 – 
100nM) of paclitaxel +/- 100 nM Dex for 48h. Cell death was assessed using the sulforhodamine B assay 
(see Methods above). Percentage of cell death was averaged over three experiments and significance of 
mean cell death was analyzed using the Student’s t-test (GraphPad). 
Retrospective analysis of early-stage ER-negative BC tumor NR3C1 gene expression association 
with RFS in TNBC subtypes 
A gene expression database of TNBC gene arrays was downloaded from GEO and is summarized 
in Supplementary File 1. Gene expression levels were normalized using MAS5 as described previously 
(38). TNBC molecular subtypes were defined by Pietenpol et al (1). TNBC patients were classified 
according to NR3C1 gene expression (Affymetrix probeID 216321_s_at) being in the top quartile of 
expression versus all others. The cutoff values were determined based on all patients in a given group. 
RFS was estimated using the method of Kaplan-Meier and compared between patients in the top quartile 
of NR3C1 expression vs. all others using the logrank test. Hazard ratios (HRs) were estimated using Cox 
proportional hazards regression models.  
Retrospective analysis of early-stage ER-negative BC tumor gene expression association with RFS 
in Discovery and Validation cohorts 
The Discovery cohort was assembled using a subset of n=68 ER-negative BC patients who 
received adjuvant chemotherapy (See Supplementary Table 1). Duplicate patients were removed, ESR1 
status was validated, and data were normalized as previously reported (30). The independent Validation 
set of n=199 ER-negative BC patients who received adjuvant chemotherapy was obtained from ten 
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studies (Supplementary Table 1); duplicate patients were removed, ESR1 status was validated, and data 
were normalized as previously reported (38). Per the REMARK guidelines, a description of the tumor 
characteristics and a study design flowchart for the Discovery and Validation cohorts can be found in 
Supplementary File 1. The GRsig was determined as follows: Differentially-expressed genes from the cell 
line microarray experiment that were induced or repressed by Dex and modulated by GR antagonists were 
cross-evaluated against a list of differentially-expressed GR-high vs. GR-low ER-negative primary BCs 
(30), to obtain a subset of n=420 genes. Next, these n=420 genes were filtered by best available 
Affymetrix probeID as defined by the Jetset method (39) to obtain a list of n=320 genes. Individual gene 
association with RFS using the Cox proportional hazards regression model with continuous expression as 
a predictor was determined for the n=320 genes, and a GRsig was defined as those with RFS-associated p 
≤ 1 x 10-5, and a HR > 1.5 for GC-induced genes or HR ≤ 0.67 (1/1.5) for Dex-repressed genes. To test 
the GRsig in both the Discovery and Validation cohorts, normalized expression levels of the 74 genes 
were added (Dex-upregulated genes) or subtracted (Dex-repressed genes) to obtain GRsig expressions. 
Patients were classified as having high GRsig expression if their GRsig expression was above the median 
GRsig expression among all n=354 ER-negative patients. RFS in each adjuvant chemotherapy group 
(Discovery and Validation cohorts) was estimated using the method of Kaplan-Meier, and was compared 
using the logrank test. Hazard ratios (HRs) were estimated using Cox regression models.  
Microarray data analysis of patient-derived xenografts (PDXs) from the Mayo Clinic neoadjuvant 
breast cancer study (BEAUTY)  
The BEAUTY trial patient-derived xenografts (PDX) were pathologically confirmed to be of human 
breast carcinoma origins and assayed by the Affymetrix HTA 2.0 microarray platform (40). Xenografts 
derived from basal TNBCs were selected for the analysis. There were a total of n=62 xenografts derived 
from n=13 baseline (V1) TNBC patient tumors; the biological replicates (multiple xenografts from same 
tumor source) were aggregated by their probeset expression means. Replicated xenografts all shared a 
median correlation (Spearman) above 0.85. The probe features of the array dataset were reduced to the 
genes provided in the GRsig. Three of these genes were assayed by two probesets each and were included 
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if they shared a correlation (Spearman) greater than 0.65 (which excluded the MUC5AC probe). The 
NOX5 gene was excluded from the analysis since the probeset did not exist in the Affymetrix HTA 
microarray platform. The GRsig expression level was derived by summing the expression profiles for the 
genes designated as Dex-induced and subtracting the summarized profiles for genes designated as Dex-
repressed. Samples greater than or equal to the median were classified as GRsig-high; the remainder (less 
than median) was considered GRsig-low. A violin plot of the expression data was generated in R using 
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High GR transcript associates with poor RFS across TNBC subtypes. 
Unique gene expression signatures, discovered and refined by Pietenpol and co-workers (1), have 
allowed TNBCs to be classified into basal-like 1, basal-like 2, mesenchymal, and LAR subtypes, 
collectively named the TNBCtype-4. In light of our previous finding that high GR/NR3C1 tumor gene 
expression from early-stage ER-negative BC patients associated with poor RFS (30), we asked whether 
high tumor GR/NR3C1 transcript expression retained an association with poor outcome in these TNBC 
subtypes. A retrospective meta-analysis of gene expression was performed using n=623 TNBC tumors 
(38). Kaplan-Meier estimates of RFS in TNBC patients in the highest quartile of tumor GR/NR3C1 
mRNA expression (versus all others) are shown in Figure 1 for each of TNBC subtypes: basal-like-1 
(n=171), basal-like-2 (n=75), mesenchymal (n=175), and LAR (n=202). We found that high tumor 
GR/NR3C1 mRNA expression was significantly associated with poor RFS in the basal-like 1 (hazard ratio 
[HR]=1.87, p=0.013), mesenchymal (HR=1.65, p=0.040), and LAR (HR=1.68, p=0.015) subtypes. High 
GR/NR3C1 association with poor RFS was not significant in the basal-like 2 subtype. Together, these 
data suggest that GR expression levels, and by extrapolation, GR activity, can stratify most ER-negative 
BC patients.  
 
The selective non-steroidal GR modulator C297 is comparable to the steroidal mifepristone in GR LBD 
affinity and chemosensitization of TNBC cells.  
We next sought to understand how relatively high GR transcriptional activity (reflected by 
increased GR expression levels) might lead to chemoresistance and a more aggressive tumor phenotype. 
We used the agonist dexamethasone (Dex, 100 nM) to mimic a patient’s endogenous circulating GC and 
activated tumor GR. We first performed an in vitro GR ligand competition assay to choose effective 
antagonists for this study. Selective non-steroidal GR modulators aryl pyrazole azadecalin C297 (35), 
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pyrimidinedione CORT118335 (C335) (41), as well as the GR/PR steroidal antagonist mifepristone 
(Mif), all potently displaced fluorescently-labeled Dex (F-Dex) from the GR ligand binding domain 
(LBD) with low nanomolar affinities (Supplementary Figures 1A and 1B). As expected, we did not 
observe GC competition using dihydrotestosterone (DHT as a negative control). The published GR 
modulator Compound A (CpdA), previously shown to displace H3-Dex in cell lysates (42), did not 
displace F-Dex from the GR LBD in our competition assay (Supplementary Figures 1A and 1B). This 
implies that regions outside the GR LBD are required for CpdA action on GR (43). We also 
immunoblotted for GR after thirty minutes or four hours of treatment with Dex, Dex/Mif, Dex/C297, or 
Dex/C335 and found that GR steady-state protein levels were not affected by the antagonists 
(Supplementary Figure 1C). The Western blot also demonstrated the expected GC-induced degradation of 
GR (44). Because C335 has been reported to also bind the mineralocorticoid receptor (41), which can be 
expressed in TNBC, C297 and Mif were selected to further characterize GR transcriptional and functional 
activity. 
We previously found that treatment with physiological concentrations of GCs decrease TNBC 
sensitivity to chemotherapy in vitro and in vivo (22,23). This suggests that GR activation in TNBCs may 
contribute to chemotherapy resistance in tumor cells following GR activation by endogenous cortisol. 
Indeed, we have also found that GR antagonism by Mif could counteract the effects of GC activation on 
tumor cell survival and thus increase paclitaxel cytotoxicity both in vitro and in vivo (24). To determine if 
non-steroidal C297 could likewise increase chemosensitivity in GR-positive TNBC, we first tested C297-
altered paclitaxel cytotoxicity in two cell lines, MDA-MB-231 and SUM-159-PT. We observed that 
treatment with GC (Dex, 100nM) dampened paclitaxel (10 nM) cytotoxicity, while the addition of the GR 
antagonist C297 (1 µM) caused a modest, but significant, relative increase in paclitaxel cytotoxicity in 
vitro (Figure 2A). As was seen previously with Mif in ER-negative cell lines (21,24), C297 treatment 
alone did not reduce cell viability (Supplementary Figure 2A). This suggests that C297 antagonism of GR 
activity increases cell susceptibility to paclitaxel-induced cytotoxicity rather than causing cytotoxicity 
itself.  
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Next, we studied the in vivo effect of GR activity in paclitaxel-treated GR+ TNBC-bearing 
female SCID mice (n=23). MDA-MB-231 xenograft tumors were established subcutaneously in the 
mammary fat pad of 6-week old female mice. When tumors reached a volume of 100 – 300 mm3, mice 
were randomly assigned to treatment groups such that each group had an approximately equal average 
tumor volume. Mice were then treated daily for five days with intraperitoneal C297 (or vehicle), 
administered one hour prior to paclitaxel. The one-hour pre-treatment with GR antagonist was intended to 
compete with endogenous GC (murine corticosterone and cortisol) bound to the tumor cell GR LBD and 
inhibit tumor GR-mediated transcription. The 5-day (5d) sequential dosing was selected to mimic the 
most effective weekly paclitaxel adjuvant chemotherapy schedule used in early-stage TNBC. However, 
extending daily treatments beyond 5d resulted in toxicity. Following cessation of the 5d treatment, time to 
tumor xenograft re-growth was measured to reflect time to patient relapse post-treatment (24,26). 
Consistent with previous in vivo results with Mif pre-treatment followed by paclitaxel (24), we observed a 
significantly increased time to tumor re-growth following C297/paclitaxel treatment compared to 
vehicle/paclitaxel (Figure 2B). Similar to the observations in vitro, C297 monotherapy did not cause a 
significant delay in tumor re-growth (Supplementary Figure 2B), suggesting that GR antagonism alone is 
neither cytotoxic nor sufficient to delay tumor progression in a TNBC model. These data are also 
consistent with C297 GR antagonism increasing chemotherapy sensitivity by reversing endogenous 
glucocorticoid-mediated expression of genes encoding anti-apoptotic proteins. These data further suggest 
that as with the non-selective GR antagonist Mif, selective GR antagonism can inhibit GR-mediated 
chemotherapy resistance both in vitro and in vivo, thereby delaying the time of tumor re-growth. 
 
GR antagonism identifies GR-regulated transcriptional pathways related to chemoresistance and 
tumor aggressiveness. 
Having established that both C297 and Mif displace GC at the GR LBD, increase chemotherapy 
sensitivity in the context of GC-activated GR, and also delay in vivo TNBC growth in comparison to 
chemotherapy alone, we next sought to define which GR-regulated genes were relevant to tumor cell 
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survival. We first used genome-wide gene expression profiling to identify GC-altered gene expression. 
We then used signatures of antagonist-altered GC-regulated gene expression to determine the subset of 
GR-regulated genes commonly antagonized by Mif or C297. Using a GR-induced or repressed transcript 
expression cut-off of at least +/-1.3 fold-change over vehicle treatment, GC treatment (Dex 100 nM) 
resulted in n=2,719 upregulated genes and n=3,202 downregulated genes at 4, 8 and 12 hours combined 
(Figure 3A). Markedly fewer genes were altered (in comparison to vehicle) upon co-treatment with either 
GR modulator (n=1,548 upregulated/1,416 downregulated for Dex/Mif, and n=1,904 upregulated/2,324 
downregulated for Dex/C297, Figure 3A). Interestingly, about half of the GC-mediated genes 
(upregulated: 50%, n=1363; or downregulated: 41%, n=1321) were unique to Dex treatment 
(Supplementary Figure 3A). A principal components analysis of the differentially altered gene signatures 
for the three treatments revealed that the Dex/Mif signatures were more closely correlated with the 
Dex/C297 signatures than to the Dex signatures at their respective timepoints (Supplementary Figure 3B). 
These data imply that Dex/Mif and Dex/C297 antagonize the GC-induced GR transcriptional profile and 
modulate a common subset of genes.  
We next sought to identify a core subset of GR-regulated genes whose activation or repression 
was commonly antagonized by C297 and Mif treatment. We found n=3,066 genes for which both GR 
modulators antagonized GR induction or repression by at least 25% (Figure 3B, Supplementary Figure 
3C). Interestingly, 87% of the C297-antagonized GR-regulated genes were also regulated in the same 
direction by Mif, whereas about two-thirds (68%) of the Mif-antagonized GR-regulated genes were 
shared with C297. These data suggest that Mif is less selective for GR than C297 and/or that Mif is the 
more potent GR modulator at 100 nM. Because both Mif and C297 displaced GC at the GR LBD and 
enhanced GR+ TNBC chemosensitivity in vivo, these n=3,066 commonly GR-regulated genes were 
further considered as candidate GR activity genes relevant to poor prognosis ER-negative BC.  
To identify the subset of the commonly antagonized GR-regulated genes (n=3,066 from Figure 
3B) that might contribute to higher relapse of ER-negative BC, we next used a meta-analysis dataset of 
primary early-stage ER-negative tumor gene expression signatures. We previously identified n=5,170 
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tumor-derived genes that were differentially expressed in GR-high versus GR-low tumors from n=354 
ER-negative BCs (30). We found n=462 genes were shared between the n=3,066 genes that were 
commonly antagonized by C297/Mif and the n=5,170 tumor-derived genes from GR-high versus GR-low 
primary BCs (Figure 3C). These n=462 genes were expressed in the same direction, i.e., a Dex-
upregulated gene was overexpressed in the GR-high versus GR-low gene list. To better characterize the 
GR gene expression networks, we performed pathway analysis on the n=462 antagonist-
modulated/tumor-relevant genes from Figure 3C. Exploring known pathway functions in cancer cells 
using Ingenuity Pathway Analysis (IPA), we found that these GR-regulated genes were significantly 
associated with cancer cell survival (inhibition of apoptosis), tumor cell invasion, and epithelial-to-
mesenchymal transition pathways. Shown in Table 1, the combination of a positive or negative pathway 
activation Z-score in the GC (Dex) treatment, and a relative dampening of Z-score magnitude upon the 
addition of either Mif or C297, confirmed antagonism of these GR activated and inactivated signaling 
pathways. This finding suggests that antagonized GR network genes contribute to tumor relapse and 
chemotherapy resistance through recognized cell viability pathways. Moreover, these GR-regulated gene 
expression networks appeared reversible using GR antagonists. 
 
GR antagonism reduces GR promoter association  
The subset of putative direct GR target genes among the n=462 GR-altered/patient-relevant genes 
from Figure 3C was next identified using GC-activated GR chromatin association data from MDA-MB-
231 cells. To achieve this, we performed GR ChIP-sequencing in cells treated with vehicle, GC (Dex), 
Dex/Mif, or Dex/C297. After normalizing GR peaks from treated conditions with vehicle, we found 
n=8,448 Dex genome-wide GR peaks, n=6,361 Dex/Mif GR peaks, and n=11,198 Dex/C297 GR peaks 
(Figure 4A, top). When examining Dex genome-wide GR peaks, we observed that only 7% (n=652) Dex 
GR peaks were conserved in the Dex/Mif treatment whereas 17% (n=1,434) Dex GR peaks were 
conserved in the Dex/C297 treatment (Supplementary Figure 4A). Motif analysis of these peaks was 
performed and transcription factor (TF) response elements (REs) were identified. Shown in Figure 4B, the 
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most significant ligand-bound GR binding regions (GBRs) were found at GR response elements (GREs), 
regardless of treatment condition. Furthermore, we found some common GR enrichment at FOXO and 
POU REs in all three treatments, however these REs were less significantly represented with both Dex 
and Dex/C297 treatments compared to the Dex/Mif treatment. AP1 and ELK REs were only shared 
between Dex and Dex/C297 treatments, and were lost with Dex/Mif treatment. These data suggest that 
although Mif and C297 have many shared effects on GR-mediated gene expression, they appear to have 
distinct effects on global GR chromatin association. 
While we observed genome-wide relative enrichment of activated GR (upon treatment with GC) 
with promoter regions, there was a decrease in relative GR promoter enrichment (+/- 3kb) following co-
treatment with either Mif or C297. This suggests that these antagonists preferentially decrease GR 
association near the transcriptional start sites (TSSs, Supplementary Figure 4B), while relatively 
increasing GR chromatin association at more distal (putative enhancer) regions. We next annotated GR 
peaks to the nearest TSSs using a maximum allowable distance of 100kB from peak to TSS (Figure 4A, 
bottom). When we limited the GR peak analysis to +/- 100kb of the TSS, GC treatment induced a robust 
genome-wide GR enrichment within 1kb of annotated TSSs, while GR association in this region was 
relatively decreased following the addition either GR antagonist (Figure 4C). This suggests that GR 
antagonists may function, at least in part, through preferentially displacing GR from proximal promoter 
regions. Interestingly, there was an overall increase in GR chromatin association (peak numbers) with 
C297 treatment; however, again the lack of peak overlap between Dex and Dex/C297 treatments 
represents a redirection to new chromatin regions more distal to TSSs (Figure 4A, Figure 4C, and 
Supplementary Figure 4B).  
To identify putative direct GR target genes whose expression was antagonized by either Mif or 
C297, we next determined the subset of n=462 tumor-relevant genes (from Figure 3C) with Dex-GR 
peaks within +/- 100kb of their TSS (Figure 4A). We found n=232 putative direct GR target genes with 
significant Dex GBRs within 100kb, suggesting either promoter or enhancer interaction by GC-activated 
GR. Indeed, several previously characterized GR target genes were identified within this list, such as 
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SGK1, DUSP1/MKP1, and GILZ/TSC22D3. Additionally, the n=232 putative direct GR target genes also 
include those with known involvement in cancer cell chemoresistance and evasion of apoptosis (MCL1, 
MUC1, GADD45B, DNAJC15/MCJ), epigenetic modification and metabolism (NMMT, SLC2A3/GLUT3, 
ACSL1, SP110), metastasis and invasion (CYR61, TGFB2, EIF4E, F2R/PAR1), angiogenesis (KDR, 
EIF4E, CALD1), and inflammation (IL15, IL1R1, IL7R, IRAK3). We selected five of these GR target 
genes with well-established cancer cell growth regulatory functions (SGK1, DUSP1/MKP1, TSC22D3, 
MCL1, NNMT) and validated antagonist-modulated gene expression by Q-RT-PCR in MDA-MB-231 or 
SUM-159-PT cells (Supplementary Figures 5A and 5B). Furthermore, the transient knockdown of two 
individual GR target genes of interest in TNBC (MCL1 and NNMT) increased paclitaxel cytotoxicity 
(Supplementary Figures 5C and 5D). We also selected two putative direct GR targets related to cell 
growth (CDKN2D) and transcriptional regulation (ZNF189) to validate by ChIP-qPCR. Dex-induced GR 
enrichment for ZNF189 which was inhibited by Mif and C297 (Supplementary Figure 4C). Finally, an 
examination of GR chromatin association within 100kb +/- of the TSS for these n=232 putative direct GR 
target genes revealed that the majority of Dex GBRs were lost upon Mif or C297 co-treatment 
(Supplementary File 2). These n=232 genes make up gene expression pathways for which GR appears to 
be a common upstream TF and for which GR antagonists reverse GC-mediated gene expression.  
 
A GR activity signature (GRsig) has a stronger association with RFS than GR expression alone. 
We next identified a GC-mediated gene set reflective of tumor-relevant GR activity and clinical 
outcome. To do this, we analyzed the association between RFS and tumor expression using the n=462 
(from Figure 3C) putative indirect and direct GR target genes with optimal Jetset Affymetrix probes. 
Next, using a Discovery cohort of n=68 ER-negative BC patients who received adjuvant chemotherapy (a 
dataset we previously reported (30), Supplementary Table 1), we determined individual gene association 
with RFS using a Cox proportional hazards regression model with continuous expression as a predictor. 
We formed a putative GR activity signature (GRsig) by selecting the most significantly RFS-associated 
genes using a stringent cut-off criteria including: RFS-associated p ≤ 1 x 10-5, and a HR > 1.5 for GC-
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induced genes or HR ≤ 0.67 (1/1.5) for Dex-repressed genes (Figure 5 and Figure 6A). From this, we 
obtained an n=74 gene GRsig (Figure 6B and Supplementary Table 2). Of the genes in the GRsig, about 
42% (n=31, were putative GR direct target genes (Figure 6A middle, and Supplementary Files 2 and 3). 
For these direct GRsig target genes, nearly all of the Dex GBRs (within +/- 100kb of each GRsig gene 
TSS) were lost upon addition of either Mif or C297 (Figure 6A bottom, Supplementary Files 2 and 3).  
We then compared RFS between ER-negative patients with high (above-median of all ER-
negative BC patients) and low (below-median of all ER-negative BC patients) tumor GRsig expression in 
the same Discovery Cohort (n=68) from which the signature was derived. As expected, patients with high 
tumor GRsig expression had worse RFS (HR = 8.1; p = 2.3 x 10-10, Figure 6C). To validate this signature 
in another group of patients, we examined the GRsig in an external (non-overlapping) Validation Cohort 
of n=199 ER-negative BC early-stage and chemotherapy-treated patients (Supplementary Table 1). A Cox 
regression model revealed that patients with high tumor GRsig expression had significantly shorter time 
to relapse compared to those with low GRsig expression (HR= 1.9; p= 0.012, Figure 6D). Interestingly, 
the GRsig associated more significantly with poor RFS in the Validation Cohort compared to NR3C1 
(GR) expression alone (Supplementary Figure 6). To determine if the GRsig was specific to ER-negative 
BCs, we split the GRsig expression at the median expression for n=1,024 ER-positive patients in our 
dataset published previously (30) and compared RFS of below and above the median tumor GRsig 
expression. We found no significant difference in RFS between the low- and high-GRsig expression 
groups, (p-value = 0.33, logrank test, Supplementary Figure 7). Taken together, these data imply that a 
GR signature derived from GR antagonist-reversed genes is a better indicator of pro-tumorigenic GR 
activity than GR expression alone. Secondly, the GRsig may stratify high-risk patients with ER-negative 
BC who would likely benefit from the addition of GR antagonists to standard chemotherapy.  
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Discussion  
 
The identification of molecular targets that play a critical role in TNBC chemoresistance and 
recurrence is important for the development of more effective BC therapies. Given the diverse subtypes of 
TNBC, it seems unlikely that only one molecule will be a master regulator of poor prognosis. Recently, 
GR has been identified as an upstream regulator of important pro-oncogenic pathways through its ability 
to affect transcription and remodel chromatin. By immunohistochemistry, 40% of ER-negative BCs were 
reported to be GR-positive (at least 10% GR staining) (33). Previous reports from our laboratory (30) and 
others (25,33) have found a significant association between high tumor GR expression and shortened RFS 
in early-stage ER-negative BC patients, suggesting that GR-mediated regulation of gene expression 
contributes to chemotherapy resistance and shortened RFS. Because endogenous cortisol-activated GR is 
a transcriptional regulator of thousands of direct and indirect target genes that vary in individual cell types 
(45,46), identifying those GR-regulated genes that are most relevant to TNBC prognosis and treatment is 
challenging.  
Both the GR/PR antagonist Mif (24) and the highly-selective GR antagonist C297 increase 
chemotherapy sensitivity in TNBC models. Here we asked whether improving chemotherapy efficacy 
occurs in association with antagonism of a specific subset of GR regulated genes. To define those GR 
targets that represent this tumor-relevant subset of GR activity, we identified GR target genes that were 
commonly inhibited by both C297 and Mif and further selected a subset that were also associated with 
high- versus low-GR expression in primary ER-negative BCs (filtering criteria shown in Figure 5). GR 
antagonists were powerful tools for identifying this important subset of genes because of their functional 
activity in increasing tumor chemosensitivity. We used primary tumor gene expression datasets to derive 
a 74-gene GRsig associated with shortened RFS in ER-negative BC patients who received adjuvant 
chemotherapy. This GRsig is hypothesized to select high-risk TNBC patients most likely to benefit from 
the addition of a GR antagonist to adjuvant chemotherapy. 
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While GR/NR3C1 cellular expression levels are predicted to correlate with GR activity (as has 
been shown for ER (47)), many factors contribute to an individual tumor’s GR activity level. The relative 
expression of nuclear receptor coregulators and cooperating transcription factors influence cell-type 
specific nuclear receptor activity (48,49). Other modifiers of GR activity include the varying expression 
and activity of GR isoforms (50), post-translational GR modification (51), and the allosteric effect of 
chromatin landscape (52). These variables result in highly specific networks of GR target genes 
depending upon cellular context. For example, we previously reported that GR activation in ER+ BC 
increases the expression of pro-differentiating genes (31). However, as expected in this study of ER-
negative BC, these pro-differentiating genes are not among the n=462 tumor-derived and GC-regulated 
genes shown in Figure 3C. The ER-negative GRsig derived here likely reflects gene expression 
specifically observed in early-stage ER-negative BCs.  
Efforts to develop highly-selective and pharmacologically active GR antagonists have led to the 
discovery of several steroidal and non-steroidal chemical compounds. To determine clinical relevance, 
GR antagonists must be studied in the presence of endogenous GCs. Effective mechanisms of GR 
antagonists include the displacement of cortisol from the GR LBD as well as functional antagonism of 
GR-mediated transcription. Additionally, discovery of context-specific GR activity signatures can be used 
in the future to characterize a novel GR modulator as an “agonist” or “antagonist” in a cancer subtype-
specific manner. Previously, GR modulators have been typically classified using in vitro binding assays 
and GR reporter gene assays. The resulting agonist/antagonist designation is somewhat artificial, because 
GR modulation is entirely dependent on cell type.  
A recently completed Phase-I clinical trial of Mif given before administration of nab-paclitaxel to 
decrease anti-apoptotic tumor cell gene expression found that combining GR antagonism with 
chemotherapy appears to be safe and tolerable (34). A Phase-I clinical trial of the highly-selective GR 
antagonist CORT125134 [an azadecalin structurally related to C297(53)] in combination with nab-
paclitaxel in solid tumors is currently underway (NCT02762981). Also, a Phase-II randomized clinical 
trial of Mif (versus placebo) with nab-paclitaxel in patients with advanced-stage TNBC has been recently 
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activated (NCT02788981). While there is some concern that a potent GR antagonist might increase 
chemotherapy-induced side effects (because Dex is used to reduce chemotherapy-associated nausea), thus 
far, the Phase-I studies only suggest a potential for increased cytopenias (34). This will be further 
investigated in the upcoming randomized Phase-II trial of nab-paclitaxel +/- Mif.  
Similar to previous discovery methods for clinically useful gene expression panels [e.g. the 21-
gene recurrence score for ER-positive BC (47)], the GRsig identified here includes retrospective tumor 
gene expression data. However, we also used potent GR antagonists (with known efficacy against TNBC 
models) to screen for to identify a subset of GR target genes also reversed by the antagonists. To begin to 
determine the predictive value of the GRsig in neoadjuvant TNBC and TNBC models, we evaluated the 
relative GR activity (via the GRsig) in n=64 individual patient-derived xenograft (PDX) tumors from 
n=13 TNBC patients enrolled in the Mayo Clinic BEAUTY trial (40,54). We found that tumors from the 
n=9 patients with pathological complete response (pCR) had a lower median GRsig expression than PDX 
tumors from n=4 non-pCR patients (Supplementary Figure 8). These preliminary data suggest that pCR 
tumors have relatively decreased GR activity, consistent with their decreased chemotherapy resistance 
and lower risk of relapse (55). In future studies, we will examine the high versus low GRsig-expressing 
PDX tumors for relative chemotherapy response +/- a GR antagonist, with the underlying hypothesis that 
GR antagonism will be most effective in significantly improving chemotherapy sensitivity in GRsig-high 
(i.e. relatively chemotherapy-resistant) PDX models. Ultimately, a randomized prospective clinical trial 
of neoadjuvant paclitaxel +/- a GR antagonist can allow testing the GRsig as a biomarker for improved 
outcome and RFS through addition of a GR antagonist to standard chemotherapy. The strong association 
of the GRsig identified here with recurrence risk in adjuvant chemotherapy-treated ER-negative BC 
suggests a path forward for identifying those patients at highest risk of relapse who are also more likely to 
benefit from selective GR antagonism. 
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Figure Legends: 
 
Figure 1. High NR3C1 (GR) expression is associated with worse outcome in TNBC subtypes. 
Kaplan-Meier estimates of relapse-free survival in patients in the top quartile (versus all others) of tumor 
NR3C1 expression. NR3C1 expression association with RFS was analyzed in TNBCs classified (1) as (A) 
basal-like 1 (NR3C1-high n=43, NR3C1-low n=128), (B) basal-like 2 (NR3C1-high n=19, NR3C1-low 
n=56), (C) mesenchymal (NR3C1-high n=44, NR3C1-low n=131), (D) luminal AR (NR3C1-high n=57, 
NR3C1-low n=145).  
 
Figure 2. GR activation inhibits chemotherapy-induced cytotoxicity of cultured TNBC cells and 
selective GR antagonism increases sensitivity to chemotherapy in vivo. (A) MDA-MB-231 and SUM-
159-PT cells were treated with paclitaxel alone (Pac, 10nM), with Vehicle, Dex (100nM), Dex/Pac, or 
C297(1μM)/Dex/Pac. C297 restored cytotoxic sensitivity at 96 hours (MDA-MB-231) and at 72 hours 
(SUM-159-PT) following Pac. The bars represent the average percentage cell death of n=3 independent 
experiments and error bars represent standard error of the mean (S.E.M). * = p value <0.05 and ** = p 
<0.01 (unpaired Student’s t-test) when compared to Dex/Pac. (B) MDA-MB-231 tumor xenograft re-
growth is significantly inhibited by C297 (20 mg/kg/day) pre-treatment one hour prior to Pac (10 
mg/kg/day) compared to Pac alone. Arrows refer to administration of Pac/Veh +/- C297/Veh. Pac-treated 
tumor re-growth was significantly smaller than vehicle, p<0.05, while C297/paclitaxel versus paclitaxel 
alone delayed post-treatment tumor re-growth significantly. The dotted line represents a 6x increase in re-
growth of tumor volume; time to tumor re-growth to this size was 18d (Veh), 27d (Pac), and 40d 
(Pac/C297). The asterisk (*) represents p < 0.05, comparing C297/Pac to Pac alone. Both C/297 vs Pac 
and Pac alone vs Veh were significantly different based on a repeated measures ANOVA and the Holm-
Sidak post-hoc significance test (Veh/Veh n=3, Veh/Pac n=6 and C297/Pac n=9).  
 
Figure 3. Differentially expressed GR target genes following GR antagonism. Genome-wide gene 
expression profiling was performed on MDA-MB-231 cells treated with GC (Dex) or GC/antagonist. (A) 
Total number of up- and downregulated genes by Dex or Dex/GR inhibitor treatment (relative to vehicle); 
(B) Subset of Dex-regulated genes (≥1.3-fold Dex vs. vehicle) reversed by C297 and/or Mif at 4, 8, and 
12h by ≥25 percent change. (C) GR antagonist-identified genes ((B), n=3,066) overlapped with genes 
(n=5,170) that were differentially expressed between GR-high versus GR-low primary tumors (30). 
N=462 genes were overlapped. 
 
Figure 4. GR chromatin association is altered by concomitant treatment with a GR antagonist. (A) 
Genome-wide GR peaks and associated genes annotated to TSSs +/- 100kB of these peaks; (B) GR 
chromatin association with transcription factor response elements (REs) following Dex and GR antagonist 
treatment reveals significant changes in GR enrichment at GREs, AP1 and ELK REs compared with Dex 
alone (CentriMO); (C) GR chromatin association in proximal promoter regions (0-3kb from the TSS) is 
diminished following Dex/Mif or Dex/C297 treatment while more distal GR peak association is 
proportionally increased.  
 
Figure 5. Identification schema for the GR activity signature (GRsig). Genes that were Dex-regulated 
and inhibited at least 25% by Mif and C297 were identified in MDA-MB-231 cells (n=3,066). Next, the 
subset of genes also differentially expressed in the same direction in GR-high versus GR-low ER-negative 
BCs was identified (n=462). GR ChIP-seq determined putative GR direct target genes as having GR 
associated within 100kb of the gene TSS (n=232). A GR “activity signature” (GRsig) was identified 
based on their univariate association with RFS (HR ≥1.5 or HR ≤ 0.67; and p ≤ 1e-5) in the Discovery 
cohort of early-stage ER-negative BC patients with adjuvant chemotherapy. The GRsig comprised of 
n=74 genes which 1) included genes that  were associated with poor RFS (HR ≥ 1.5) and were Dex-
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upregulated and 2) genes that were associated with improved RFS (HR ≤ 0.67) and were Dex-
downregulated. This GRsig was applied to the Discovery and an independent Validation cohort of early-
stage patients treated with adjuvant chemotherapy. 
 
Figure 6. Patients with above-median expression of the 74-gene GR activity signature (GRsig) have 
significantly decreased relapse-free survival. Genes in the GRsig were selected from among the n=462 
tumor-relevant and antagonist-reversed Dex-regulated genes based on their univariate association with 
RFS in the Discovery cohort (HR ≥1.5 or HR ≤0.67; and p < 1e-5). (A) Summary of GRsig genes (top 
line) and their Dex-mediated up- and downregulation, and the subset of GRsig genes that are putative 
direct GR target genes (middle line) with loss of GR peak with Dex/antagonist treatment (bottom line). 
(B) List of individual GRsig genes, separated by their Dex-mediated up- or down-regulation with bolded 
gene names indicating putative direct GR target genes. (C, D) Kaplan-Meier estimates showing that the 
above-median GRsig expression (versus all others) is associated with RFS in both the Discovery and 
Validation cohorts.  
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TABLE 1 
Table 1. GR antagonists diminish cell survival and tumor metastasis functions while  



























synthesis of lipid 1.91 0.68 0.83 4 46 
invasion of tumor cell lines 0.63 -0.03 0.35 4 53 
colony formation of tumor cell lines (invasion) 0.14 0.02 -0.52 4 24 
epithelial-mesenchymal transition of breast cell lines 0.11 -0.34 -0.22 4 9 
metastasis of tumor cell lines 2.05 1.03 1.22 8 16 
transactivation 1.62 -0.44 -0.28 8 39 
cell survival 1.53 -1.28 0.69 8 99 
cell proliferation of colorectal cancer cell lines 0.72 -1.23 -0.71 8 27 
cell transformation 0.22 -1.55 -1.29 8 42 
invasion of tumor cells 1.43 0.26 0.29 12 15 
growth of tumor 0.77 0.47 0.24 12 63 




















 cell death of tumor cells -1.57 -0.55 -0.30 4 35 
cytostasis of tumor cell lines -1.60 0.77 1.03 4 15 
contact growth inhibition of tumor cell lines -1.77 0.09 0.52 4 13 
benign neoplasia -2.35 -0.03 -1.49 4 63 
inflammatory response -0.14 2.12 1.94 8 54 
cytostasis of tumor cell lines -1.01 -0.45 0.35 8 15 
contact growth inhibition of tumor cell lines -1.02 -0.39 0.51 8 13 
apoptosis -1.06 0.41 1.11 8 162 
cell death -2.27 0.45 0.26 8 193 
development of epithelial tissue (differentiation) -1.69 0.19 -1.22 12 45 
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